Rigel Tumbles on Phase III RA Failure; Lilly Drug Misses, Too
By Catherine Shaffer
Thursday, December 13, 2012
AstraZeneca plc's top-line results from a Phase IIb study of fostamatinib in rheumatoid arthritis showed that the drug was superior to placebo at six weeks, but it fell short of a secondary goal of noninferiority against Humira, sending shares of partner Rigel Pharmaceuticals Inc. plunging by almost 35 percent.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.